Co Diagnostics Stock Insiders


USD 2.77  0.01  0.36%   

Co Diagnostics employes about 101 people. The company is managed by 14 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive having 7.21 employees per reported executive. Break down of Co Diagnostics management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Co-Diagnostics future performance.
Continue to Trending Equities.
  Dwight Egan  Chairman
Chairman of the Board and Presidentident, CEO

Co Diagnostics Management Team Effectiveness

Co-Diagnostics has return on total asset (ROA) of 0.0467 % which means that it generated profit of $0.0467 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.129 %, meaning that it created $0.129 on every $100 dollars invested by stockholders. Co Diagnostics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Co Diagnostics Workforce Comparison

Co-Diagnostics is rated third in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 193,964. Co Diagnostics adds roughly 101 in number of employees claiming only tiny portion of equities under Health Care industry.

Co Diagnostics Profit Margins

The company has Profit Margin (PM) of 0.28 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.0.

Co Diagnostics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Co Diagnostics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Co-Diagnostics Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Co-Diagnostics Price Series Summation is a cross summation of Co Diagnostics price series and its benchmark/peer.

Co Diagnostics Notable Stakeholders

A Co Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Co Diagnostics often face trade-offs trying to please all of them. Co Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Co Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dwight Egan - Chairman of the Board and Presidentident, CEOProfile
Reed Benson - CFO, SecretaryProfile
Edward Borkowski - Independent DirectorProfile
Richard Serbin - Independent DirectorProfile
Edward Murphy - Independent DirectorProfile
Frank Kiesner - Independent DirectorProfile
Eugene Durenard - Independent DirectorProfile
Brent Satterfield - Chief Science Officer, DirectorProfile
Andrew Benson - Head RelationsProfile
Brian CPA - CFO SecProfile
Mayuranki Almaula - VP AlliancesProfile
Dan CPA - VP AccountingProfile
Cameron Gundry - Head LATAMEURProfile
Mark Poritz - Chief OfficerProfile

About Co Diagnostics Management Performance

The success or failure of an entity such as Co-Diagnostics often depends on how effective the management is. Co Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Co Diagnostics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Co Diagnostics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.
The data published in Co Diagnostics' official financial statements usually reflect Co Diagnostics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Co-Diagnostics. For example, before you start analyzing numbers published by Co Diagnostics accountants, it's critical to develop an understanding of what Co Diagnostics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Co Diagnostics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Co Diagnostics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Co Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Co-Diagnostics. Please utilize our Beneish M Score to check the likelihood of Co Diagnostics' management to manipulate its earnings.

Co Diagnostics Workforce Analysis

Traditionally, organizations such as Co Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Co Diagnostics within its industry.

Co Diagnostics Manpower Efficiency

Return on Co Diagnostics Manpower

Revenue Per Employee969.2 K
Revenue Per Executive7 M
Net Income Per Employee363 K
Net Income Per Executive2.6 M
Continue to Trending Equities. Note that the Co-Diagnostics information on this page should be used as a complementary analysis to other Co Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Co Diagnostics Stock analysis

When running Co-Diagnostics price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Is Co Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Co Diagnostics. If investors know Co Diagnostics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Co Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
86 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Co-Diagnostics is measured differently than its book value, which is the value of Co Diagnostics that is recorded on the company's balance sheet. Investors also form their own opinion of Co Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Co Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Co Diagnostics' market value can be influenced by many factors that don't directly affect Co Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Co Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Co Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Co Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.